Stock of the Day: After Today’s Significant Increase, Is Karyopharm Therapeutics Inc’s Near-Term Analysis Positive?

Stock of the Day: After Today's Significant Increase, Is Karyopharm Therapeutics Inc's Near Term Analysis Positive?

The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a huge mover today! About 162,337 shares traded hands. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has declined 31.22% since April 4, 2016 and is downtrending. It has underperformed by 32.31% the S&P500.
The move comes after 8 months positive chart setup for the $228.42M company. It was reported on Nov, 4 by We have $9.70 PT which if reached, will make NASDAQ:KPTI worth $91.37M more.

Analysts await Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report earnings on November, 14. They expect $-0.77 earnings per share, up 9.41% or $0.08 from last year’s $-0.85 per share. After $-0.84 actual earnings per share reported by Karyopharm Therapeutics Inc for the previous quarter, Wall Street now forecasts -8.33% EPS growth.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage

Out of 11 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 10 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 91% are positive. Karyopharm Therapeutics Inc. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Canaccord Genuity initiated Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, December 22 with “Buy” rating. On Tuesday, March 15 the stock rating was downgraded by Bank of America to “Underperform”. As per Wednesday, January 6, the company rating was downgraded by Jefferies. Robert W. Baird initiated the shares of KPTI in a report on Tuesday, June 28 with “Outperform” rating. The firm has “Outperform” rating by Raymond James given on Friday, May 27. Jefferies upgraded Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, August 30 to “Buy” rating. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, August 18 report. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) has “Buy” rating given on Wednesday, August 12 by MLV. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock has “Buy” rating given by H.C. Wainwright on Thursday, September 8.

According to Zacks Investment Research, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.”

Insitutional Activity: The institutional sentiment increased to 1.54 in Q2 2016. Its up 1.01, from 0.53 in 2016Q1. The ratio increased, as 11 funds sold all Karyopharm Therapeutics Inc shares owned while 15 reduced positions. 10 funds bought stakes while 30 increased positions. They now own 19.84 million shares or 5.28% less from 20.95 million shares in 2016Q1.
State Street accumulated 0% or 371,372 shares. American Intll Gru last reported 13,602 shares in the company. New York State Common Retirement Fund owns 36,966 shares or 0% of their US portfolio. Ubs Asset Mngmt Americas Inc reported 10,500 shares or 0% of all its holdings. Moreover, Ellington Gru Inc Limited Liability Co has 0.15% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 16,200 shares. Endurance Wealth Mgmt accumulated 0.01% or 6,000 shares. Stoneridge Prns Limited Liability holds 0.03% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 32,465 shares. Tekla Mngmt Limited Co holds 500,324 shares or 0.14% of its portfolio. The New York-based Tiaa Cref Invest Mngmt Ltd Liability Corporation has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Tfs Cap Ltd Co last reported 49,883 shares in the company. Geode Capital Mgmt Limited owns 143,471 shares or 0% of their US portfolio. Tcw Group holds 41,652 shares or 0% of its portfolio. Northern, a Illinois-based fund reported 257,473 shares. The Florida-based Thomas J Herzfeld Advsr has invested 0.02% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Moreover, Palo Alto Invsts Ltd has 1.59% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 3.14M shares.

Insider Transactions: Since May 10, 2016, the stock had 0 insider buys, and 10 insider sales for $3.86 million net activity. $801,806 worth of Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares were sold by Chione Ltd.

More recent Karyopharm Therapeutics Inc (NASDAQ:KPTI) news were published by: which released: “Karyopharm Therapeutics Inc. (Nasdaq: KPTI) to Ring The Nasdaq Stock Market …” on November 03, 2016. Also published the news titled: “Why Karyopharm Therapeutics Inc Shares Are Soaring 31% Today” on August 30, 2016.‘s news article titled: “Why Karyopharm Therapeutics Stock Is Falling Today” with publication date: September 06, 2016 was also an interesting one.

KPTI Company Profile

Karyopharm Therapeutics Inc., incorporated on December 22, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The Company’s segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Firm has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company’s lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. The Firm is also engaged in the clinical development of selinexor in various solid tumor indications. The Firm has initiated various later-phase clinical trials to evaluate selinexor in hematological cancers and solid tumors. The Firm has also initiated a double-blinded, placebo-controlled, randomized Phase II/III study of single-agent selinexor in liposarcoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment